Development and validation of genomic biotypes for schizophrenia susceptibility from multiple polygenic scores

Ersoy Kocak[*1,2], Joonas Naamanka[*1,2,3], Tobias Gradinger[*1,2], Fiona Klaassen[1,2], Johannes Nitsche[1,2], Philipp Grotehusmann[1,2], Kristina Adorjan[4,5], Linda A Antonucci[6], Giuseppe Blasi[6,7], Monika Budde[4], Piergiuseppe Di Palo[6,7], Maria Heilbronner[4], Gianluca C Kikidis[6], Alba Navarro-Flores[4,8], Mojtaba Oraki Kohshour[4,9], Sergi Papiol[4,10,11], Alessandra Raio[6], Antonio Rampino[6,7], Daniela Reich-Erkelenz[4,10], Eva C. Schulte[4,10,12,13,14], Fanny Senner[4,10,15], Leonardo Sportelli[16], FinnGen[17], Alessandro Bertolino[6,7], Peter Falkai[10,11,14], Urs Heilbronner[4], Giulio Pergola[6,16,18], Thomas G. Schulze[4,14,18,19], Andreas Meyer-Lindenberg[1], Fabian Streit[#1,2,20], Emanuel Schwarz[#1,2,20]

1, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2, Hector Institute for Artificial Intelligence in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
3, SleepWell Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
4, Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, Munich, Germany
5, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland
6, Department of Translational Biomedicine and Neuroscience, University Of Bari Aldo Moro, Bari, Italy
7, U.O.C. Psichiatria Universitaria, Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy
8, International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Max-Planck-Institute of Psychiatry, Munich, Germany
9, Department of Immunology, Faculty of Medicine, Ahvaz, Iran
10, Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, Germany
11, Department Clinical Translation, Max Planck Institute of Psychiatry, Munich, Germany, Munich, Germany
12, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Bonn, Bonn, Germany
13, Institute of Human Genetics, Faculty of Medicine and University Hospital Bonn, Bonn, Germany
14, German Center for Mental Health (DZPG), partner site Munich/Augsburg, Germany
15, Centres for Psychiatry Suedwuerttemberg, Centres for Psychiatry Suedwuerttemberg, Ravensburg, Germany
16, Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA
17, The full list of FinnGen members can be found as a supplementary table
18, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
19, Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, NY, USA
20, German Center for Mental Health (DZPG), Partner Site Mannheim - Heidelberg - Ulm, Germany

* Contributed equally
# Co-senior authors

Corresponding author
Prof. Dr. Emanuel Schwarz
Phone: +4962117032390
Email: emanuel.schwarz@zi-mannheim.de

Abstract

Understanding the genetic architecture of schizophrenia (SCZ) is invaluable for the development of personalized treatment. In three independent cohorts, using an automated pipeline, we calculated 413 psychiatry-relevant polygenic scores. Using these scores, machine learning was applied to stratify SCZ patients into two biotypes in FinnGen (n_{SCZ}=7486), and to validate these results in the PsyCourse Study (n_{SCZ}=421) and Bari (n_{SCZ}=531). While the two biotypes showed comparable polygenic SCZ risk, they were primarily distinguished by a greater predisposition for neuroticism, depression-related traits, and lower cognitive performance in Biotype 1. The genetic prediction of Biotype 1 was phenotypically characterized by an increased prevalence of SCZ and a more severe and complex clinical manifestation. This illustrates that the penetrance of genetic SCZ risk might partially depend on the predisposition for the aforementioned traits through pleiotropic variants. Our results provide novel, replicable insights into the genetic architecture of SCZ and might inform future personalized treatments.

Introduction

Schizophrenia (SCZ) is a severe and complex mental disorder with a lifetime prevalence estimate of up to 1%, an incidence peak in early adulthood, and an often chronic course[1]. The severity of the disease is evident in many epidemiological metrics, e.g., an approximately 15-year reduction in life expectancy[2] and the fact that only 10-20% of affected individuals are in competitive employment[1,3,4].

The phenotypic complexity of the disease is reflected in its manifestations with multiple domains like perception (e.g., hallucinations), affect (e.g., flattening of affect), cognition (e.g., cognitive deficits), behavior (e.g., loss of drive), speech (e.g., schizophasia), motor skills (e.g., catatonia), and autonomic regulation (e.g., pernicious catatonia) being affected to varying degrees among patients. Although diagnostic systems have long specified a phenotypic subclassification of SCZ, these classifications have been dropped from ICD-11 and DSM-V for lack of reliability and clinical utility[5]. Furthermore, the complexity and heterogeneity of SCZ is reflected in the treatment response: approximately one third of the patients do not respond to standard treatment[6,7], and especially a subgroup of symptoms, commonly referred to as negative symptoms (e.g. flattening of affect and avolition[8,9]) often persist..

The biological complexity of the disease warrants strongly multimodal and multi-level approaches[1]. Evidence suggests that SCZ encompasses a multitude of overlapping neurobiological processes[10]. SCZ cases that are similar regarding those processes can be considered to belong to a biotype, i.e., a biologically more homogeneous subgroup within the disorder. Identifying those biotypes is an approach towards personalized medicine and a more refined understanding of the disease etiology[11]. Across a number of family and twin studies, heritability for SCZ has been estimated at 60%-80% overall[12–14], among the highest for psychiatric disorders, and shows the strongest positive genetic correlation with bipolar disorder (BIP, genetic correlation (rg) ~ .7) , but also with other mental disorders such as major depression (MDD; rg ~ .35)[14,15]. Additionally the phenotypic and biological heterogeneity of SCZ has been hypothesized to depend in part on genetic heterogeneity[16–18]. Therefore, the investigation of genetic variation is a promising base for identifying its possible biotypes[1,19,20]. Genome-wide association studies (GWAS) of SCZ indicate it is a highly polygenic disorder with thousands of common risk variants, i.e. primarily single nucleotide polymorphisms (SNPs), each exerting a small effect on overall disorder risk[15,21]. To estimate the genetic predisposition of an individual to a disease or a trait, the effects conferred by individual SNPs can be summed up into polygenic scores (PGS), also often referred to polygenic risk scores (PRS) in the case of diseases and adverse traits. These indices of polygenic predisposition

show robust predictive performance in independent samples but they fall far short of explaining
disease liability to the degree suggested by heritability estimates, including the ones
accounting for common variation only[19,22].

Therefore, considered together with the high genetic intercorrelations and overlapping
phenotypic constructs in psychiatry[22], an approach based on a broad spectrum of PGS seems
promising. Furthermore, SCZ PGS are primarily designed to distinguish cases from controls
which makes a multi-PGS strategy better suited for discriminating cases from other cases.
While the PGS of SCZ, combined with additional psychiatric PGS with known comorbidity with
SCZ, have been used as the basis for identifying biotypes[23], recent advances in machine
learning and data harmonization have been demonstrated to allow for a data-driven multi-PGS
approach, resulting in improved predictive performance compared to single-PGS models[24].

Building on this recent research we aimed to: i.) identify genetic risk biotypes of SCZ by
integrating large numbers of PGS of psychiatry-relevant phenotypes using robust,
reproducible machine learning methods; ii.) characterize these biotypes as patient subgroups
that demonstrate specific patterns of polygenic risk contributions from a potentially large
number of phenotypes iii.) characterization of these biotypes in terms of clinical
manifestations.

To achieve this, we developed *PRS*cope, a new automated framework for biotype
identification and validation using multi-PGS data. Our analysis included data from a total of
8,442 patients with SCZ, and 28,327 healthy controls (HC) from three independent datasets,
to identify and validate biotypes. In addition we used 7,555 patients with BIP, 27,187 patients
with MDD, and 41,998 HCs for a transdiagnostic analysis.Our method offers a novel approach
to deconstructing the genetic heterogeneity of complex human disorders and may contribute
to the personalization of medical care in SCZ and other mental disorders.

Results

The PRScope procedure comprises three overarching steps: I) the retrieval of information
from publicly available "source" GWAS, to compute quality-controlled PGS; II) the training of
machine learning models using PGS derived from different numbers of source GWAS that are
associated with SCZ; and III) the identification and validation of "biotypes" of SCZ that relate
to subgroups of patients that share a similar composition of PGS signals. The number of
source GWAS used for machine learning is denoted as *feature size* (though the actual number
of features may be higher since PGS were calculated for multiple significance thresholds).

Identification and validation of genetic biotypes of SCZ

PRScope retrieves GWAS summary statistics based on the selected Experimental Factor Ontologies (EFO) categories from the EFO browser (www.ebi.ac.uk/efo) and performs filtering and quality control. We applied it to psychiatry-related categories (selected EFO categories can be found in Supplementary Table 1, for more details see section Methods) which yielded 413 source GWAS for the subsequent PGS calculation in the target datasets (Train$_{FinnGen}$, Val$_{PsyCourse}$, and Val$_{Bari}$).

We applied this procedure to data from the FinnGen cohort[25] (Train$_{FinnGen}$; 7486 patients with SCZ and 27288 HC, for more demographic details, see Supplementary Table 2-4) and calculated PGS at 10 significance thresholds (from 5×10^{-8} to 1) for 413 source GWAS applying a commonly used simple method, clumping and thresholding[26]. Bayesian approaches for calculating PGS[27–29] may outperform this method, particularly when comparing the single PGS derived from the Bayesian methods with that obtained using the best p-value threshold. However, our approach can offer the advantage of leveraging information from all SNP layers defined by different significance thresholds, combining all PGS derived from a GWAS within a multi-PGS framework. To identify biotypes using the multi-PGS data, we first extracted the features in the training folds of 10-fold cross validation. To do this we determined the best p-value threshold (i.e strongest correlation with SCZ) for PGS derived from each source GWAS and ranked the source GWAS based on the correlations of these best-threshold PGS with SCZ. The PGS of the top 45 source GWAS were selected for further analyses (note that PGS with all p-value thresholds were kept even though the ranking was based on the best ones only, see Methods for details). The following steps were applied for each feature size from 1 to 45 separately in the training folds. First, the SCZ patients were classified into two biotypes via k-means clustering. Second, a random forest (RF) model was trained for each of the two biotypes predicting SCZ vs HC. This approach was used to validate that the identified biotypes reflect disease-specific PGS patterns. Third, SCZ vs HC predictions were made in the test folds with each biotype model, resulting in one prediction for Biotype 1 model and one prediction for Biotype 2 model per feature size. Finally, every SCZ patient being uniquely correctly predicted by one of the biotype models was then assigned to this biotype (for more details see section Methods and for a schematic overview of the procedure, see Figure 1). This cross-validation procedure showed that once at least five of the most relevant features on top of the SCZ PGS were added, the predictions of both Biotype 1 and 2 models were positively associated with the true disease status ($p < 0.05$ after Benjamin-Hochberg (BH) correction; Figure 2a, for uncorrected p-values see Supplementary Table 5). This illustrates that using such numbers of PGS the biotypes could be successfully predicted in independent test data. Next, we evaluated the stability of the biotypes with respect to the selected feature

size. With an increasing feature size the nature of the biotypes changed (Figure 2b), and we
observed a substantial reallocation of patients, which started leveling off with approximately
12 PGS (Figure 3).
Thus, we decided to predict the biotypes at feature sizes that represent the points of a high
rate of reallocation (see Methods for details) into two validation datasets (Val$_{PsyCourse}$[30], n=421
patients with SCZ and n=300 controls, Supplementary Table 3; Val$_{Bari}$, n=535 patients with
SCZ and n=739 controls, Supplementary Table 4). Similarly to Train$_{FinnGen}$ cross-validation, in
both validation datasets (Val$_{PsyCourse}$ and Val$_{Bari}$), we observed that both Biotype 1 and 2 were
significantly positively associated with SCZ from feature size 6 onwards ($p < 0.05$ after BH
correction, see for uncorrected p-values and the biotype proportions in patients and HC
Supplementary Table 6-10), although for Val$_{PsyCourse}$ the p-value exceeded 0.05 (shown as a
dip due to the negative log transformation) for the Biotype 2 model at feature size 24
(Figure 2a). The biotypes did not significantly differ concerning age, sex, or population
stratification principal components (PCs) in any of the three datasets.

The top SCZ associated PGS fall into three groups

As many of the top 45 selected features were conceptually similar (e.g., different neuroticism
items, see Figure 3) we set out to investigate if they could be grouped empirically. To
achieve this we calculated all pairwise genetic correlations for those 45 GWAS using LDSC
software[31,32] and applied hierarchical clustering to the resulting correlation matrix (using
absolute values). Based on a visual inspection of the dendrogram (Supplementary Figure 1)
we assessed a four-cluster solution to be the most interpretable one. The clusters, for the
remainder of the article referred to as *PGS groups*, can be characterized as relating to
cognition, depression and neuroticism. The final group includes SCZ itself, a gene-
environment interaction of neuroticism and two alcohol traits. As they had relatively low
genetic intercorrelations (Supplementary Figure 2) and were conceptually not easy to
reconcile, we decided not to treat them as a group of their own.

SCZ risk penetrance coincides with the genetic predisposition to neuroticism, depression-related traits, and low cognitive performance.

Figure 2 shows that the PGS driving biotype composition besides SCZ-PGS, were the ones
relating to neuroticism, depression-related traits, and cognition. It highlights that while both
biotypes featured comparable risk for SCZ towards the higher feature sizes, they substantially
diverged concerning the other PGS. Specifically, Biotype 1 was characterized by a markedly
elevated neuroticism PGS group and a relatively low cognition PGS group, whereas Biotype

2 displayed an opposite pattern for neuroticism and intermediate (between Biotype 1 and HC)

levels for the cognition PGS group.

The contribution of neuroticism to SCZ risk is mediated by shared genetic variation

Since SCZ has well-established genetic correlations with neuroticism, depression, and

cognition[21,33], and the better-performing Biotype 1 model is characterized by these

dimensions, we investigated whether these aspects were collectively reflected as

disproportional risk contributions of pleiotropic SNPs.

For this, we constructed a subset of PGS of SNPs that were associated with SCZ and each of

the PGS groups. We utilized the conjunctional false discovery rate analysis (conjFDR)[34] with

an FDR of 0.1 (see Methods for details). All three of these subset PGS predicted SCZ better

than PGS constructed of p-value matched (as indicated in the SCZ GWAS summary statistics)

SNPs outside their respective pleiotropy SNP group (Figure 4). Supplementary Table 11-13

show the pleiotropic variants as identified by conjFDR.

Genetic biotypes have transdiagnostic relevance and differ in clinical

measures

To support the clinical validity of the identified biotypes, differences in clinical features were

assessed across the investigated datasets. These analyses were, in addition to conventional

covariates, corrected for the SCZ-PGS, to capture biotype effects independent of genetic

predisposition for SCZ (see section *Phenotypic profiling* in the Methods). All phenotypic results

are shown for feature size 24 only for simplicity of illustration (for other feature sizes see

Supplementary Figure 3-18). In $Train_{FinnGen}$, Biotype 1 was associated with a more severe and

complex clinical manifestation in patients with SCZ as indicated by higher rates of clozapine

and antidepressant prescriptions and comorbid psychiatric diagnoses; including depression,

neurotic, personality, and eating disorders (Figure 5). Both in $Val_{PsyCourse}$ and Val_{Bari} the

statistical power of the phenotypic analysis was substantially lower than in $Train_{FinnGen}$ due to

a far smaller sample size. Still in $Val_{PsyCourse}$, the higher rate of clozapine prescription in Biotype

1 could be replicated, while the higher rate of antidepressant prescription could not, though it

was showed as a trend (Figure 5). Both in $Val_{PsyCourse}$ and Val_{Bari} the Positive and Negative

Syndrome Scale (PANSS) showed no significant differences in any of the scales (Figure 5).

In $Val_{PsyCourse}$ we further investigated a collection of phenotypic variables representing the

major risk components of the biotypes as represented by the PGS groups defining them. We

found a significantly (FDR corrected p-values < 0.05) higher score for Biotype 1 in the

Inventory of depressive symptomatology (IDS-C$_{30}$) (Figure 5). In $Train_{FinnGen}$, Biotype 1 model

predictions were also associated with BIP (n cases = 7,555; n controls = 11,198) and MDD (n

cases = 27,187; n controls = 26,993) in a gradient-dependent manner, with the highest OR

observed for SCZ, intermediate for BIP, and the lowest for MDD. The corresponding

associations for Biotype 2 model predictions followed the same gradient-dependent pattern,

but the magnitude of the association was lower, for MDD even in the other direction (OR < 1,

$p = 0.018$) (Figure 6).

Figure 1. Overview of the PRScope framework and analysis pipeline. a) Psychiatry-related GWASs, annotated with relevant ontologies and fulfilling our filtering criteria, were downloaded from the GWAS Catalog and pre-processed for the subsequent PGS calculation. **b)** Overlapping SNPs across the three datasets were pre-processed and PGS calculations for 413 pre-processed GWAS summary statistics were performed for each GWAS summary statistic using up to 10 different significance thresholds. **c)** Machine learning analysis steps were used to identify two biotypes with differing PGS profiles in a large-scale training dataset, followed by validation in two independent datasets. (i) Selection of GWASs with the strongest association to diagnosis to reduce the dimension to improve the clustering performance and the predictive power of the ML models. To prevent data leakage during cross-validation in the training dataset, feature selection was performed separately for each cross-validation

iteration. For validation, features were extracted using the entire training dataset. (ii) Biotyping

was based on different numbers of features (from top 1 to top 45) using k-means clustering.

The PGS of selected GWASs for SCZ patients were adjusted by subtracting the median and

dividing by the standard deviation of the HC. (iii) Random forest machine learning was applied

to characterize the multi-PGS signature of each biotype. (iv) Biotype memberships were

predicted by the model in independent data and cross-validation test folds. **d)** The

characterization of the predicted biotypes as subgroups of patients that demonstrate specific

patterns of polygenic risk contributions from a potentially large number of phenotypes. (i)

Associations between the predicted biotype memberships and diagnosis were quantified as

the odds ratio and the significance was determined using two-sided Fisher's exact test. (ii)

The beta values derived from the logistic regression represent the association between the

PGS of selected GWAS summary statistics and biotype membership. The table used as a

legend shows the GWASs grouped together based on their genetic correlation. (iii) PCs were

calculated for each group separately (Biotype 1, Biotype 2, and HC) using all PGS of a GWAS

group, and the mean values of the first PC for each group across different feature sizes were

plotted. **e)** The k-means clustering solution for a given feature size was compared with the

clustering results of other feature sizes and visualized as a heatmap. **f)** To support the clinical

validity of the identified biotypes, differences in clinical features were assessed across the

investigated datasets.

Figure 2. Results of biotype validation. a) The odds ratios (OR) and the significance
(adjusted p-values) across the three datasets were determined using two-sided Fisher's exact
test where the input was a cross table of either Biotype 1 or Biotype 2 model and SCZ. The
(BH)-adjusted p-values were -log10 transformed to increase the readability of the plot. The
raw p-values can be found in Supplementary Tables (5-7) and the biotype proportions in
patients and HC can be found in Supplementary Tables (8-10). Feature sizes 1 to 45 (x-axis)
were plotted so that the development of the profiles of the clusters could be demonstrated
when more and more features were added to the clustering/prediction procedure. An OR
larger than 1 (dashed line) means that a prediction of having SCZ by a given model increases
the odds of truly having SCZ. The red lines on the p-value plots denote the BH-adjusted p-
value of the significance threshold (0.05). **b)** The PGS compositions of the biotypes and HC
were visualized across the three PGS groups (neuroticism, depression, and cognition-related
PGS groups) and SCZ PGS. The mean of the first PC (to ensure comparability across units
of analysis, all measures were scaled) of each PGS group was plotted across the feature sizes
from 1 to 45 (x-axis) for Biotype 1, Biotype 2, and HC.
291
292

Figure 3. PGS composition of the biotypes and stability across the feature sizes. The polar plot was generated using the FinnGen cohort's association results for the features size 45. To facilitate comparison across PGS groups, the PGS of a PGS group were successively plotted. The table in the figure shows the ranked order of the selected GWASs that showed the strongest correlation with the diagnosis. The associations between each GWAS summary statistic from the top 45 GWASs and biotype membership predicted by the model trained on these features were estimated using logistic regression. ARI heatmap was generated using the FinnGen cohort's k-means clustering results for the feature sizes from 1 to 45. ARI was calculated directly using the whole sample prediction results. To facilitate comparison across features, 0.7 is selected as the threshold for high similarity. Detailed information about the GWASs can be found in Supplementary Table 14 and the values used to create the polar plot can be found in Supplementary Table 15. The ARI values used to generate the heatmap can be found in Supplementary Table 16.

Figure 4. Predictive performance of the conjFDR-based PGS in Train_{FinnGen}**.** The
diamonds indicate the odds ratios for a PGS constructed with conjunctional FDR with a given
GWAS group (see Methods) in a logistic regression where true SCZ status was the dependent
variable. The boxplots represent estimates from similar models with different PGS serving as
predictors. Each PGS was constructed on a p-value-matched random sample of SCZ risk
SNPs. The p-values are derived from Cochran's Q test of heterogeneity of effects, where the
maximum estimate and the corresponding standard error from the 100 respective comparative
PGS are contrasted with the conjFDR PGS.

Figure 5. Phenotypic profiling of Biotype 1 and Biotype 2. Feature size = 24. Baseline: Biotype 2. All comparisons are adjusted for the SCZ PGS, sex, and age. In $Val_{PsyCourse}$ and Val_{Bari} additionally adjusted for center/study; all results with the 95% CI (displayed) not overlapping the null effect are also significant with an FDR of 0.05 applied within each category (for comorbid disorders only the significant ones are shown); analyzed case numbers of Biotype 1 and Biotype 2 are listed in brackets ($n_{Biotype\ 2}$ / $n_{Biotype\ 1}$): Clozapine (105/88), Antidepressants (105/88), PANSS = Positive and Negative Syndrome Scale, positive, negative, general and total score ($Val_{PsyCourse}$ 98/115, Val_{Bari} 84/86). CGI = Clinical global impression (99/115), GAF = Global Assessment of Functioning (98/115), Neuroticism = Dimension from Personality (74/85), $IDS-C_{30}$ = Inventory of depressive symptomatology (97/113), BDI-II = Beck Depression Inventory-II (88/103), DST = Digit-Symbol-Test (98/110), Digit s. fwd = Verbal digit span forward (98/112), Digit s. bwd = Verbal digit span backward (98/112), TMT B-A = Trail making test part B - part A ($Val_{PsyCourse}$ 96/104), MWT-B = Multiple-Choice Vocabulary Intelligence Test (67/81). For all FinnGen analyses, the corresponding group sizes are (2621/3044).

332
333 **Figure 6. Differential diagnostic associations of SCZ biotypes.** The odds ratios (OR) are

334 derived from two-sided Fisher's exact test where the input was a cross table of either Biotype

335 1 or Biotype 2 model (x-axis) and a disorder. The error bars show 95% confidence intervals.

Discussion

In the present study, we aimed to comprehensively capture the genetic risk architecture of SCZ through the simultaneous investigation of patients' susceptibility to psychiatry-relevant phenotypes using 413 publicly available GWAS, leveraging an exceptionally large training dataset (Train$_{FinnGen}$). We asked whether patient subgroups exist that differ in the risk patterns related to these phenotypes and identified two reproducible biotypes in large-scale data. Our approach leverages the large statistical power of the original genotype data the PGS were derived from, as well as the power of machine learning to identify clinically meaningful biotypes from the large number of PGS. We classified patients into two biotypes, one of which was characterized by high common-variation genetic risk for neuroticism-related phenotypes and depression-related phenotypes and low PGS for cognitive traits (Biotype 1), whereas the other biotype (Biotype 2) had a polygenic profile similar to HC in those dimensions. While the biotypes exhibited approximately the same elevated levels of genetic risk for SCZ, a machine-learning model based on Biotype 1 clearly outperformed a model based on Biotype 2 in predicting SCZ in independent validation datasets (Val$_{PsyCourse}$ and Val$_{Bari}$). Furthermore, Biotype 1 patients tended to have clinical manifestations that indicate higher rates of treatment resistance and complexity. The predictions of the machine learning models based on both biotypes had the strongest association with SCZ, an intermediate one with BIP, and the weakest with MDD.

While previous studies have demonstrated that simple disease prediction can be improved with a multi-PGS approach[24], our results demonstrate the utility of using this approach for data-driven clustering of patients concerning differing genetic biotypes. Notably, the results indicate that stable and reproducible biotypes could be identified once several PGS (more than 5) were included in the machine-learning procedure. With a lower number, the biotypes were largely defined by their level of SCZ PGS and failed to capture the multi-phenotypic risk architecture observed at higher feature sizes. One remarkable observation of our study was, that while not substantially differing in SCZ risk load, the model based on Biotype 2 was a significantly weaker predictor of SCZ case status than the model based on Biotype 1. There are several potential explanations for this finding that are not mutually exclusive. First, the genetic risk contributions for neuroticism, depression-related traits, and low cognitive performance may reflect biological mechanisms necessary for the disease risk to elevate significantly. While the corresponding genetic risk may be captured by SCZ PGS, it may be that it is merely underweighted in the PGS calculation. Another hypothesis would be one where the SCZ genetic risk estimation is more accurate in Biotype 1 than in Biotype 2 patients. In this scenario, the higher levels of polygenic risk of non-schizophrenia traits/disorders in

Biotype 1 would suggest higher prevalence of alleles that confer risk to both SCZ and some
other related trait (i.e they are pleiotropic). These pleiotropic SNPs could be more often truly
causal for SCZ than the ones only associated with SCZ risk as the additional associations can
be considered as an increase in the strength of statistical evidence, making such SNPs less
likely to be false positives even when the p-value in SCZ GWAS summary statistics would not
suggest so. Our finding that the PGS based on conjFDR SNPs are slightly better predictors
than PGS based on comparable subsets of SCZ risk SNPs lends support for this. However,
as the differences are small the conclusion must be considered suggestive.

Biotype 1 yielded a superior predictive model compared to Biotype 2 and was also associated
with multiple clinically relevant measures, which collectively point towards higher illness
severity and complexity in Biotype 1. Notably, the observed phenotypic profiles of the biotypes
closely reflect the PGS groups defining them. This link between genetic liability and actual
phenotype is further substantiated by the gradual emergence of the phenotypic profiles with
increasing feature sizes (Supplementary Figure 3-18). The explanation for Biotype 1 being the
more predictive model and having a higher likelihood for treatment resistant cases (as
suggested by the higher likelihood for clozapine use) while having the same genetic SCZ
liability, it can be speculated that this might be a result of the interaction between the
predisposition for neurotic, depressive, and cognitive traits associated with Biotype 1. Higher
neuroticism and lower cognitive ability may reduce stress-coping ability, leading to higher SCZ
penetrance in Biotype 1, as stress is one of the main environmental risk factors for SCZ[35–37].
Lower stress coping ability can also lead to maladaptive coping strategies like drug use, a well
established trigger for psychosis[38]. Accordingly, the link between Biotype 1 and depression-
related phenotypes (increased rates of affective comorbidities and antidepressant use and a
significantly higher score on a depression specific questionnaire; Figure 5) might be driven by
both a higher genetic liability for depression related traits and neuroticism, as neuroticism is a
known risk factor for MDD and they have a high positive genetic correlation[39–42]. An important
notion is that while SCZ PGS has been linked to clinical characteristics within SCZ patients
(Bipolar Disorder and Schizophrenia Wo...), the current approach goes beyond the
identification of subtypes that would have been possible using the SCZ PGS This is also
indicated by the observation that all of the phenotypic associations survived adjustment for
SCZ PGS. For example, the association with clozapine use was not attenuated by controlling
for SCZ PGS (though, SCZ PGS has previously been linked to clozapine dosage within SCZ
patients who take it, see [43]). Using a set of well-selected PGS for cognition and neuroticism
may have produced similar results but the fact that our data-driven approach arrived at these
theoretically sensible dimensions can only be seen as a strength. Additionally the data-driven

approach allowed us to determine which PGS are not important in the context of SCZ biotype

identification.

For all its strengths, the current study has several limitations. First, the method by which we

assigned the patients to biotypes left some of them without one, as a correct classification was

required by exactly one of the prediction models. Second, by no means do our findings

suggest there are exactly two biotypes. As one of the main goals of this study was

reproducibility and thus considering the sample size limitations of the validation datasets, we

restricted the analysis to classify patients into two biotypes. Third, our method only considered

genetic predisposition to psychiatry-related traits. It is possible that the inclusion of genetic

risk in somatic domains would improve the classification and provide more insight into

underlying biological mechanisms[44–46]. Fourth, the heterogeneity between the datasets we

used in terms of the availability of phenotypic data hampered us from conducting more

harmonized analyses in that regard, drawing less definite conclusions about generalizability.

On the other hand, the fact that our procedure works across such different datasets can be

seen as an indication of good portability. Finally, as only samples of European descent and

GWAS from that ancestry were used, the findings presented in this paper are not valid for non-

European ancestry individuals. For our pipeline to become applicable to those populations

better-powered GWAS from non-European ancestries are needed[47,48].

In summary, our data-driven machine learning scheme successfully leveraged a large number

of psychiatry-related PGS, for the first time, to derive two biotypes of SCZ patients. A

prediction model based on Biotype 1, broadly speaking characterized by high neuroticism and

depression related traits and low cognitive functioning, is a promising step toward identifying

SCZ patients with a poor prognosis at an early stage. It may also prove to be useful in

personalizing treatments, a prospect that would need to be evaluated in a randomized and

controlled clinical trial. The current study was focused on SCZ but in the future, it could be

applied to any phenotype, psychiatric or somatic.

Methods

Overview of method

The aim of the multi-PGS approach, pursued in this study, was to better characterize the

genetic architecture of SCZ by the combined analysis of polygenic risk of a large number of

psychiatry-relevant phenotypes. For this, we implemented PRScope which extracts GWAS

summary statistics from the GWAS Catalog[49]. Phenotypes were automatically selected based

on study annotations, the corresponding GWAS summary statistics were quality controlled

and the PGS was then determined in a target genotype dataset. Care was taken to ensure
that the target genotype datasets did not contain data overlapping with that of the GWAS
summary statistics in the GWAS Catalog, to prevent potential bias. The PGS for the large
number of phenotypes (multi-PGS) was then used for machine learning, to identify biotypes
of SCZ that differed in their respective composition of associated PGS. These biotypes were
identified in a large-scale training dataset, and validated in two independent validation
datasets.

Multi-PGS calculation framework

The combined analysis of PGS for different phenotypes faces several challenges, including
data consistency issues arising from heterogeneous file formats and naming conventions
(related to data as well as phenotypes), differences in genome assemblies, and variant
orientation regarding DNA strands. The GWAS Catalog addresses these issues by
harmonizing and categorizing summary statistics from published GWASs and making them
accessible on a single platform. The harmonization is carried out by the *harmonizer pipeline[50]*,
which aligns variants to the desired genome assembly and reference data. The categorization
is performed using the EFO[51], which annotates GWAS summary statistics with consistent
terminology. Furthermore, the GWAS Catalog provides a user-friendly interface for querying
the database by criteria such as phenotype, gene, SNP, trait, or study. These features of the
GWAS Catalog enabled us to search for GWAS summary statistics related to the disease of
interest, automate QC steps, and determine PGS. Utilizing these features, we implemented a
pipeline consisting of four modules, each designed for independent use. Marees et al.[52] and
more recently Choi et al.[53] have published detailed protocols for the calculation of PGS. These
protocols include detailed instructions for performing quality control on genotype data and
GWAS summary statistics, as well as standards for interpreting PGS. Our approach followed
the guidelines presented by Marees, et al. and Choi, et al.

Automated GWAS search module

A primary challenge for researchers conducting multi-PGS studies is selecting source GWAS
summary statistics from among 100,000+ available GWAS summary statistics in the GWAS
Catalog. It is crucial to include GWAS summary statistics of traits that are of likely relevance
to the target phenotype, to meaningfully reduce the dimensionality of the multi-PGS data but
still be able to capture as much of the genetic architecture as possible. To address this, we
implemented a module to automate this selection process. This module uses the EFO Browser
to filter and collect relevant GWAS summary statistics files. Users first perform a preliminary
search in the EFO browser to identify relevant ontologies for the target phenotype and save

the selected EFO IDs. In the next step, they can define search criteria in the module
configuration file, such as GWAS population, number of SNPs, sample size, and publication
date (described in detail in Supplementary Methods). The module uses the R library
gwasrapidd[54] to search the GWAS Catalog for studies annotated with the specified EFO IDs,
applying the user-defined filters (see section *Filtering criteria* in the Supplementary Texts). By
running the module, users receive a list of GWAS Catalog summary statistic IDs that meet the
specified criteria (described in detail in Supplementary Figure 19).

In the present study, our strategy for ontology selection aimed at including a broad spectrum
of phenotypes relevant to SCZ. For this, we focused on psychiatry-related ontologies from
different domains such as biological, behavioral, brain development, psychiatric traits, and
psychiatric disorders. In total, we selected 23 ontologies (Supplementary Table 1) and
performed our GWAS search module to search the GWAS Catalog for GWAS summary
statistics annotated with these ontologies or their sub-ontologies. The resulting list included
413 GWAS summary statistics that met our criteria and had a harmonized version of the
respective GWAS summary statistics. Using these harmonized versions of GWAS summary
statistics led to two favorable outcomes: First, the GWAS summary statistics were transformed
into a uniform format, enabling effective calculation of PGS. Second, variants were already
mapped to the latest genome assembly and alleles were orientated to the forward strand.
Additionally, we found 1,462 relevant GWAS summary statistics that met our filtering criteria
but did not have a harmonized version (Supplementary Table 17). Furthermore, 65 GWAS
summary statistics not listed in the GWAS Catalog but accessible from PGC, CTG, and other
public sources (Supplementary Table 18-22), were prepared and included in our analysis
using the same harmonization pipeline as applied by the GWAS Catalog.

GWAS summary statistics QC module

Duplicate, ambiguous, and multi-allelic SNPs, as well as SNPs that lacked both beta value
and odds ratio, were removed from the GWAS summary statistics. The p-value was set to 1
for SNPs without a p-value (described in detail in Supplementary Figure 20).

Genotype QC module

First, SNPs and subjects were filtered based on a relaxed threshold (missing call rate of >
20%). Then a filter with a more stringent threshold was applied. Subjects with missing call
rates of > 2% were removed. Next, SNPs with missing call rates of > 2%, minor allele
frequency < 1%, and deviation from the Hardy-Weinberg equilibrium ($p \leq 1 \times 10^{-6}$) were
removed. Additionally, non-autosomal, duplicate, and ambiguous SNPs were excluded. The

R-package used to estimate relatedness was carried out as implemented in plinkQC v0.3.4[55],

by estimating the relatedness between pairs of individuals based on identity-by-state similarity

(PI_HAT > 0.1875) and retaining the subject with the lowest genotype missingness in pairs or

larger groups of related subjects (described in detail in Supplementary Figure 21). Detailed

information about the imputation and pre-imputation can be found in Supplementary Texts

(Pre-imputation and Imputation).

PLINK v1.9 was used to assess the impact of population stratification via PC analysis as

described in RICOPILI's PCA module[56]. In case the sample was bigger than 1,000 subjects,

a subset of approximately 1,000 subjects was randomly selected for the pruning of the SNP

set prior to the PCA. Similarly, if more than 1 million SNPs were present in the dataset, a

random SNP set of ~1 million SNPs was selected for pruning. For the PCA calculation, we

excluded SNPs with more than 2% missing call rates, a minor allele frequency below 5%, or

a Hardy-Weinberg equilibrium deviation ($p \leq 1 \times 10^{-3}$), and SNPs in the long-range linkage

disequilibrium (LD) regions of the Major Histocompatibility Complex region (chr 6, 25-35 MB)

and the chromosome 8 inversion region (chr 8, 7-13 MB). The remaining SNPs were pruned

using an r-squared threshold of 0.2, a window size of 200 kb, and a step size of 100 to

minimize LD, followed by a second round of pruning with the same parameters. Finally, PLINK

was used to calculate PCs for ancestry estimation for all subjects using the SNPs generated

in the previous steps.

PGS calculation module

The PGS calculation module of PRScope offers the advantage of quickly generating multiple

PGS calculations in parallel using PRSice-2[26], requiring minimal configuration. For the present

study, PGS calculations for 413 pre-processed GWAS summary statistics were performed for

each GWAS summary statistic using up to 10 different significance thresholds, representing

different levels of statistical significance for the genetic variants included in each PGS. PGS

including fewer than 500 SNPs at a given significance threshold were excluded from the

analyses. Detailed information about the PGS calculation can be found in Supplementary

Texts (PGS Calculation Parameters).

Cohort overview

The present study included data from three cohorts. Data from FinnGen release 12

($Train_{FinnGen}$) (7486/27288 cases/controls for SCZ, 7555/11198 for BIP, 27187/26993 for MDD.

Controls for BIP and MDD are partly shared, but not with SCZ controls) were used for the

identification of multi-PGS biotypes, and to test transdiagnostic associations. Data from the

PsyCourse Study ($Val_{PsyCourse}$) was used for biotype validation. Data from the Bari cohort

(Val$_{Bari}$) was used for additional biotype validation[21]. All cohorts were independent of the
original GWAS summary statistics the PGS were derived from, to prevent circularity.
Supplementary Table 2-4 show the composition of the datasets after QC with respect to
gender and diagnosis. To minimize bias due to the differences in cohorts, only the SNPs that
overlap across three datasets were included in the PGS calculation (2.925.749 SNPs from
each dataset). The Multi-PGS data in all three datasets were first checked for outliers by robust
multivariate outlier detection using the OGK estimator[57]. Based on this method, the log
distances above a threshold (≥ 4.5) were classified as outliers, often representing individuals
from different populations or those with genotyping errors. Subsequently, the Multi-PGS data
were residualized against the first 20 genetic PCs using linear regression and z-transformed.

All participants provided written informed consent (see below). Procedures were approved by
Ethics Committee II of the University of Heidelberg Medical Faculty Mannheim (protocol no.
2024-845) and the respective local ethical committees.

Study subjects in FinnGen provided informed consent for biobank research, based on the
Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish
Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were
collected based on study-specific consents and later transferred to the Finnish biobanks after
approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare
and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The
Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS)
statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers:
THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers:
VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution
(permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA
98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA
16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020,
THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020,
THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021,
THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021,
THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics
Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20)

TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases

permission/extract from the meeting minutes on 4th July 2019.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze

12 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67,

BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, BB2021_65, Finnish Red Cross

Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020,

HUS/430/2021 §28, §29, HUS/150/2022 §12, §13, §14, §15, §16, §17, §18, §23, §58, §59,

HUS/128/2023 §18, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and

amendments BB_2021-0140, BB_2021-0156 (August 26 2021, Feb 2 2022), BB_2021-0169,

BB_2021-0179, BB_2021-0161, AB20-5926 and amendment #1 (April 23 2020) and it´s

modifications (Sep 22 2021), BB_2022-0262, BB_2022-0256, Biobank Borealis of Northern

Finland_2017_1013, 2021_5010, 2021_5010 Amendment, 2021_5018, 2021_5018

Amendment, 2021_5015, 2021_5015 Amendment, 2021_5015 Amendment_2, 2021_5023,

2021_5023 Amendment, 2021_5023 Amendment_2, 2021_5017, 2021_5017 Amendment,

2022_6001, 2022_6001 Amendment, 2022_6006 Amendment, 2022_6006 Amendment,

2022_6006 Amendment_2, BB22-0067, 2022_0262, 2022_0262 Amendment, Biobank of

Eastern Finland 1186/2018 and amendment 22§/2020, 53§/2021, 13§/2022, 14§/2022,

15§/2022, 27§/2022, 28§/2022, 29§/2022, 33§/2022, 35§/2022, 36§/2022, 37§/2022,

39§/2022, 7§/2023, 32§/2023, 33§/2023, 34§/2023, 35§/2023, 36§/2023, 37§/2023,

38§/2023, 39§/2023, 40§/2023, 41§/2023, Finnish Clinical Biobank Tampere MH0004 and

amendments (21.02.2020 & 06.10.2020), BB2021-0140 8§/2021, 9§/2021, §9/2022,

§10/2022, §12/2022, 13§/2022, §20/2022, §21/2022, §22/2022, §23/2022, 28§/2022,

29§/2022, 30§/2022, 31§/2022, 32§/2022, 38§/2022, 40§/2022, 42§/2022, 1§/2023, Central

Finland Biobank 1-2017, BB_2021-0161, BB_2021-0169, BB_2021-0179, BB_2021-0170,

BB_2022-0256, BB_2022-0262, BB22-0067, Decision allowing to continue data processing

until 31st Aug 2024 for projects: BB_2021-0179, BB22-0067,BB_2022-0262, BB_2021-0170,

BB_2021-0164, BB_2021-0161, and BB_2021-0169, and Terveystalo Biobank STB 2018001

and amendment 25th Aug 2020, Finnish Hematological Registry and Clinical Biobank decision

18th June 2021, Arctic biobank P0844: ARC_2021_1001.

Machine learning analysis

The goal of the applied machine learning analyses was to identify (using Train$_{FinnGen}$) and

validate (using the Val$_{PsyCourse}$ and Val$_{Bari}$ data) subgroups of patients with SCZ with differing

multi-PGS profiles (i.e. 'biotypes'). Using the multi-PGS matrix we first determined the

respective z-score of each PGS for patients with SCZ by subtracting the median of the controls

and dividing by the standard deviation of the controls. To tune clustering to SCZ-relevant

features, we then selected the GWAS summary statistics that showed the strongest
association with the diagnosis. Clustering was based on different numbers of such
transformed PGS (from top 1 to top 45) using k-means clustering (k=2, performed using the
kcca function of the *flexclust* library)[58], to identify 2 subgroups. Clustering was repeated 100
times, the co-occurrence of subjects within a given cluster was recorded for each subject pair,
and a consensus was identified by clustering the resulting matrix. Random forest machine
learning[59] was applied to characterize the multi-PGS signature of each biotype and to predict
this signature in independent data. To characterize the PGS signature associated with each
biotype, 51-times repeated random forest machine learning (using the ranger v0.17.0 R library
with 1000 trees and default parameters)[60] was applied using under-sampling. Under-sampling
was used to balance the unequal group sizes of patients within a given biotype, and the control
group. To evaluate the reproducibility of this approach in the training data, the entire procedure
was applied within a 10-fold cross-validation. For instance, to train the model for Biotype 1,
the training folds comprised an equal number of HCs and SCZ patients assigned to Biotype
1. Then, the Biotype 1 membership was predicted by the model in the test fold and
associations between the predicted biotype memberships and diagnosis were quantified as
the odds ratio (OR). The significance was determined using two-sided Fisher's exact test. The
same approach was applied to Biotype 2. The resulting p-values were adjusted for multiple
testing (from top 1 to top 45, i.e., the number of tests: 45) using R's p.adjust function with the
BH correction method. The BH-adjusted p-values were -log10 transformed and plotted
(Figure 2a). To prevent data leakage, the z-scoring and cluster identification were performed
separately for each CV-iteration. To obtain comparable cluster assignments (as the cluster
numbering is arbitrary) across CV folds, these were aligned to the first CV-iteration based on
linear correlation obtained from predictions in overlapping training subjects.

Feature selection for clustering and prediction

Feature selection aimed at identifying the PGS that showed the strongest association with
diagnosis in order to improve the clustering performance and the predictive power of the ML
models. Our approach included all PGS calculated at different significance thresholds for
GWAS summary statistics, allowing us to fully utilize the full information provided by the
corresponding GWAS summary statistics file. To achieve this, we first grouped the PGS of a
given GWAS summary statistics into a "PGS block" and ranked these blocks based on the
"best PGS" within a PGS block that showed the strongest correlation with the diagnosis
(Supplementary Figure 22). A PGS block is composed of PGS calculated at up to 10 different
significance thresholds from a GWAS summary statistics (see Supplementary Texts, *PGS*

Calculation Parameters). For downstream analysis, all PGS of the highest-ranked blocks were
included, ranging from the top 1 to the top 45.

Investigating cluster profiles

This step aims to characterize the biotype profiles by estimating the associations between
selected GWAS summary statistics and the biotypes using logistic regression. Subjects
uniquely assigned to each biotype and the healthy control group were sampled to create
dependent variables of logistic regression. Logistic regression was then applied separately for
each best PGS of selected GWAS summary statistics to associate the biotype groups with
GWAS summary statistics as displayed in the formulas (1,2).

658                              $(1)\ Y_{model\ 1} \sim PGS_j$
659                              $(2)\ Y_{model\ 2} \sim PGS_j$

$Y_{model\ 1}$ and $Y_{model\ 2}$ are binary variables where value of 1 indicates Biotype 1 and Biotype 2,
respectively, and value of 0 indicates HC. PGS_j is the best PGS of jth GWAS summary
statistics of the top 45.

The beta values calculated by the logistic regression represent the association between the
best PGS of selected GWAS summary statistics and the biotype assignments (Figure 3).
Similarly, PCs were calculated for each group (Biotype 1, Biotype 2, and HC) using all PGS of
a PGS group. The mean values of the first PC for each group across different feature sizes
were plotted (Figure 2). For clearer interpretation we display SCZ as a single PGS.

Investigating cluster stability

The k-means clustering solution for a given feature size was compared with the clustering
results of all other feature sizes and visualized as a heatmap (Figure 3). Cluster similarities
were quantified using the adjusted Rand index[61].

Phenotypic profiling

To compare the phenotypic profiles of the two biotypes, we used a general linear model (GLM)
regressing the phenotypic variable *j* on the biotype (*n* = either 1 or 2), with the SCZ PGS on
all p-value thresholds and available demographic data used as *k* covariates using (3):

676                         $(3)\ pheno_j \sim biotype_n + cov_1 + \ldots + cov_k$

Continuous phenotypes were initially z-standardized ($\frac{x-\mu}{\sigma}$). R version 4.4.1 was used for all

statistical analyses. The glm function from the standard stats package was used to apply the

GLM as displayed in (3). In the case of binary phenotypic variables, a logistic regression with

the same covariates was performed and odds ratios are reported. As the two distinctive groups

most representative of each of the biotypes are the SCZ patients uniquely correctly identified

by either of the biotypes, we used these groups for the comparisons. All results were displayed

as forest plots showing the beta-value (or odds ratio) of the biotype and their respective 95%

confidence intervals.

The PsyCourse Study

PsyCourse is a multi-center observational longitudinal deep-phenotyping study of the

affective-to-psychotic spectrum, including healthy controls. All participants provided written

informed consent, and the study was approved by all relevant Ethics Committees (see [30]).

Demographic covariates used for the phenotypic profiling in $Val_{PsyCourse}$ were sex, age, and

center of recruitment (in addition to the SCZ PGS on all p-value threshold levels used in all

datasets). Due to the large number of recruitment sites (n=20), and the unequal distribution of

patients recruited across these sites, we focused on sites that recruited at least 20 patients

(resulting in a selection of n = 339 SCZ patients). Due to the longitudinal study design, some

of the phenotypic measures are taken at up to four time points (spread over 18 months) for

each subject. If this was the case, we used the maximum value over the time points. Due to

the sparse pattern of missings in the PsyCourse dataset, the number of available data varies

depending on the phenotypic measure. Based on the results from $Train_{FinnGen}$, we compared

the number of patients taking clozapine or antidepressants between the biotypes (this analysis

was run without controlling for center, due to the low number of cases from each center). The

information about the clozapine and antidepressant treatment was derived from the

medication dataset, a subset of the PsyCourse data set (see below). In addition to this we

analyzed phenotypic measures based on PGS defining the biotypes which could be

summarized as SCZ (Positive and Negative Syndrome Scale (PANSS): positive, negative and

general symptoms subscale and total score) and three additional major components, which

genetic predispositions mainly drive the difference between the biotypes: Cognitive function

(verbal digit span forward, verbal digit span backward, Digit-Symbol-Test (DST), Multiple-

Choice Vocabulary Intelligence Test (MWT-B), TMT B-A = Trail Making Test part B - part A),

depression-related traits (Inventory of depressive symptomatology ($IDS-C_{30}$), Beck

Depression Inventory II (BDI-II)) and neuroticism (Neuroticism = Dimension from BFI-10

questionnaire[62]). On top of these, we also added measures of overall disease severity (Clinical

global impression (CGI), Global Assessment of Functioning (GAF)). Variable names as used

in the PsyCourse codebook: https://data.ub.uni-
muenchen.de/251/1/210908_PsyCourse_v5.0.html are mapped in Supplementary Table 23.
The resulting p-values were separately FDR-corrected for each analysis block (medication,
PANSS scales, additional phenotypic variables).

Bari

Demographic covariates used for the phenotypic profiling in Val_{Bari} were sex, age and the
original study in which the data was acquired (in addition to the SCZ PGS on all p-value
threshold levels used in all datasets). The Bari dataset consists of data from two studies.
Clinical phenotypic data in this dataset was the PANSS negative sum, PANSS positive sum,
PANSS general sum, and PANSS total sum, which was available for 249 of the SCZ patients.
Other phenotypic data was also available but for only a very small number of SCZ patients.
Analogous to the approach in the PsyCourse dataset we used the max value whenever values
for more than one time point were available. The resulting p-values were separately FDR-
corrected for the PANSS scales.

FinnGen

To examine biotype differences in comorbidity of psychiatric phenotypes each phenotype was
analyzed with a separate logistic regression with biotype as a dichotomous predictor and SCZ
PGS, age, and sex as covariates. Endpoints with less than 100 cases among the SCZ patients
were excluded. Benjamini-Hocheberg multiple-testing correction was applied within a given
feature size at a false discovery rate of 0.05. The same procedure was applied for the
medication analyses (see *Phenotype definitions in FinnGen* for how medication history was
determined).

Selection of feature sizes for the full FinnGen data training

To limit the number of models to be tested in the validation data sets ($Val_{PsyCourse}$ and Val_{Bari}),
a few feature sizes were selected. This was achieved by first converting the cluster assignment
table across all feature sizes to a distance matrix (function *dist* with the method option "binary",
from the R-package *stats*[63]) and then performing hierarchical clustering (function *hclust* from
the R-package *stats*[64]) to determine feature sizes which give out similar cluster assignments.
Upon visual inspection of the resulting dendrograms, 5 clusters (see Supplementary Figure 1)
were deemed appropriate, and for each of the clusters, the lowest feature size was selected
for the full data training. Additionally, feature sizes 1 to 5 were included so that the
development of the profiles of the clusters could be demonstrated when more and more
features were added to the clustering/prediction procedure.

Formation of the PGS groups

The first step in forming the three PGS groups (cognition, depression, and neuroticism) was
to calculate genetic correlations using LDSC software for the top 45 GWASs excluding SCZ
and a trait incorporating 12 psychiatric disorders[31,32]. The European samples reference panel
from the 1000 Genomes project[65] was used for LD scoring. Then, hierarchical clustering was
performed on the absolute values of the resulting (quasi-) correlation matrix. Upon visual
inspection and theoretical consideration, a three-cluster solution was selected
(Supplementary Figure 1-2).

Subset PGS analysis

To provide insight as to why one of the cluster models predicts SCZ better than the other,
despite similar overall polygenic risk for SCZ. To investigate this we further analyzed the
polygenic SCZ risk, by assessing the contribution of genomic loci shared between the SCZ
GWAS summary statistics and the other three GWAS groups. We calculated a corresponding
subset SCZ-PGS using the SNPs with conjunction FDR<0.1 for each of the PGS groups, and
weighting the SNPs by their association in the SCZ GWAS. To achieve this, we first conducted
the conjunctional FDR[34,66] approach between SCZ GWAS summary statistics and all the other
GWAS summary statistics among the top 45. If a SNP had a conjFDR of below 0.1 with any
of the GWAS summary statistics within a PGS group (see *Formation of the PGS groups*) it
was included in the calculation of the subset SCZ-PGS of that PGS group. For example, for
the PGS group "Cognition" a corresponding subset PGS was constructed, capturing the
genetic variation relating to both SCZ and cognitive traits (i.e. pleiotropic effects). For each of
the three SNP subsets 100 p-value matched SNP sets (as indicated in the SCZ summary
statistics) of equal size were sampled from the SNPs outside of the corresponding pleiotropic
SNP set. The matching was performed with the R function *matchit* (distance = "glm") from the
package *MatchIt*[67] Different matched subsets were achieved by adding slight random error to
the p-values against which the matching was done.

After defining the SNP sets, PGS were calculated for each of them. Their predictive
performance was assessed with logistic regressions where SCZ was the outcome and a given
subset PGS the predictor. Before the analyses, all the PGS were adjusted for the first 20
ancestral PCs and then standardized. Finally, Cochran's Q test (function *rma* with method =
"EE", from the R package *metafor*[68]) was used to determine a p-value for the difference in
effect size between a subset PGS of a given GWAS group and the best corresponding
comparative PGS.

Phenotype definitions in FinnGen

SCZ, BIP, and MDD cases were selected using the specialized inpatient and outpatient, cause
of death, and drug purchase registers (coded in the data as INPAT, OUTPAT, DEATH and
PURCH, respectively). For each disorder, their respective ICD codes served as case criteria.
Additionally, individuals who had ever purchased the drug clozapine were determined as
having SCZ, as that drug is virtually never prescribed for other disorders. Lithium for bipolar
disorder or antidepressants for depression were not utilized to that end as they are more
commonly prescribed for other disorders and diseases. The disorders were regarded as
hierarchical in the way that SCZ superseded BIP which in turn superseded MDD.

For defining controls, more stringent criteria were applied. In the case of SCZ, all psychotic
disorders lead to exclusion, as well as Olanzapine, Risperidone, Amisulpride and Haloperidol
purchases. The aforementioned drugs indicate a psychotic disorder or episode, but not
necessarily confirmed SCZ. For BIP, the same criteria applied with the addition of not having
any mood disorders. Additional registers of primary health care (PRIM_OUT) and drug
reimbursement (REIMB) were used for control exclusion to add more certainty that control
subjects are truly not cases. The exact ICD codes and ATC drug codes can be found in
Supplementary Table 24.

From the remaining eligible controls a sex and age-matched sample was taken (*matchit*
function in the R-package *MatchIt*[67]) to simplify downstream analyses and to limit the number
of individuals for whom PGS needed to be calculated. The control group sizes were four times
the number of cases for SCZ and BIP and of equal size for MDD. Finally, the full sample (cases
of all disorder phenotypes and all control groups) was restricted to unrelated individuals so
that the maximum allowed degree of relatedness was 3 (e.g. first cousins). 10,000 random
selections of removal with a preference for keeping cases were performed and the one that
resulted in the least subjects getting excluded was applied.

Phenotypes for comorbidity and medication analyses

All psychiatry-related (category F5) FinnGen core endpoints served as phenotypes in the
comorbidity analyses without further modifications. Core endpoints are the ones defined by
the FinnGen core analysis team and their descriptions can be browsed at
https://risteys.finngen.fi/. For the medication analyses, clozapine use was identified with the
ATC code N05AH02, and antidepressants with the ATC category N06A as recorded in the
drug purchase register.

Acknowledgments

We thank all research participants and all researchers and clinicians who collected, generated, or processed the data used in this study. The full list of FinnGen banner authors can be found in Supplementary Table 25.

Funding

This work was supported by the Hector foundation II, the German Federal Ministry of Education and Research (BEST project, grant 01EK2101B), the German Research Foundation (DFG) (TRR 265/2 TP A06), and was endorsed by German Center for Mental Health (DZPG). U.H. was supported by European Union's Horizon 2020 Research and Innovation Programme (PSY-PGx, grant agreement No 945151) and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, project number 514201724). T.G.S. was supported by the European Union Horizon 2020 Research and Innovation Program (PSY-PGx, grant agreement No 945151), and also by the Deutsche Forschungsgemeinschaft within the framework of the projects www.kfo241.de and www.PsyCourse.de [SCHU 1603/4–1, 5–1, 7–1]. T.G.S. was further supported by the Dr Lisa Oehler Foundation (Kassel, Germany), the Bundesministerium für Bildung und Forschung (BMBF, Federal Ministry of Education and Research; projects: IntegraMent [01ZX1614K], BipoLife [01EE1404H], e:Med Program [01ZX1614K]) and European Union's Horizon 2020 Research and Innovation Programme (ERA-NET Neuron Projects GEPI-BIOPSY [BMBF No 01EW2005] and MulioBio [BMBF No 01EW2009]). G.C.K. 's PhD scholarship is financially supported by Exprivia S.p.A. under the Italian ministerial decree D.M. 351. Furthermore, this study was supported by FAIR - Future AI Research (PE00000013), spoke 6 – Symbiotic AI, under the NRRP MUR program funded by the NextGenerationEU; Project CUP : H97G22000210007, and the Apulian regional government for the project: "Early Identification of Psychosis Risk."

Conflicts of Interest

G.B. has received lecture and consultant fees by Lundbeck. A.R. has received lecture fees by Janssen. A.B. received consulting fees from Biogen and lecture fees from Otsuka, Janssen, and Lundbeck. G.P. has received lecture fees by Lundbeck. A.M.-L. has received consultant fees from: Agence Nationale de la Recherche, Brain Mind Institute, Brainsway, CISSN (Catania International Summer School of Neuroscience), Daimler und Benz Stiftung, Fondation FondaMental, Hector Stiftung II, Janssen-Cilag GmbH, Lundbeck A/S,

Lundbeckfonden, Lundbeck Int. Neuroscience Foundation, MedinCell, Sage Therapeutics,

Techspert.io, The LOOP Zürich, University Medical Center Utrecht, von Behring Röntgen

Stiftung. A.M.-L.has received speaker fees from: Ärztekammer Nordrhein, BAG Psychiatrie

Oberbayern, Biotest¨ AG, Forum Werkstatt Karlsruhe, International Society of Psychiatric

Genetics, Brentwood, Klinik für Psychiatrie und Psychotherapie Ingolstadt, Lundbeck SAS

France, med Update GmbH, Merz-Stiftung, Siemens Healthineers, Society of Biological

Psychiatry. A.M.-L. has received editorial fees from: American Association for the

Advancement of Science, Elsevier, Thieme Verlag. E.S. received speaker fees from bfd

buchholz-fachinformationsdienst GmbH and Lundbeckfonden as well as editorial fees from

Lundbeckfonden and the Wellcome Trust. The other authors have declared that there are no

conflicts of interest in relation to the subject of this study.

References

1.   Marder, S. R. & Cannon, T. D. Schizophrenia. *N. Engl. J. Med.* **381**, 1753–1761 (2019).

2.   Chang, C.-K. *et al.* Life expectancy at birth for people with serious mental illness and

other major disorders from a secondary mental health care case register in London.

PLoS One **6**, e19590 (2011).

3.   Fleischhacker, W. W. *et al.* Schizophrenia--time to commit to policy change. *Schizophr.*

Bull. **40 Suppl 3**, S165–94 (2014).

4.   Kahn, R. S. *et al.* Schizophrenia. *Nat Rev Dis Primers* **1**, 15067 (2015).

5.   Braff, D. L., Ryan, J., Rissling, A. J. & Carpenter, W. T. Lack of use in the literature from

the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and

ICD-11. *Schizophr. Bull.* **39**, 751–753 (2013).

6.   Fusar-Poli, P. *et al.* Treatments of negative symptoms in schizophrenia: Meta-analysis

of 168 randomized placebo-controlled trials. *Schizophr. Bull.* **41**, 892–899 (2015).

7.   Potkin, S. G. *et al.* The neurobiology of treatment-resistant schizophrenia: paths to

antipsychotic resistance and a roadmap for future research. *NPJ Schizophr* **6**, 1 (2020).

8.   Lincoln, T. M., Dollfus, S. & Lyne, J. Current developments and challenges in the

assessment of negative symptoms. *Schizophr. Res.* **186**, 8–18 (2017).

9.   Dollfus, S. & Lyne, J. Negative symptoms: History of the concept and their position in

diagnosis of schizophrenia. *Schizophr. Res.* **186**, 3–7 (2017).

10. Owen, M. J. New approaches to psychiatric diagnostic classification. *Neuron* **84**, 564–

571 (2014).

11. Millan, M. J. *et al.* Altering the course of schizophrenia: progress and perspectives. *Nat.*

Rev. Drug Discov. **15**, 485–515 (2016).

12. Hilker, R. *et al.* Heritability of schizophrenia and schizophrenia spectrum based on the

nationwide Danish Twin Register. *Biol. Psychiatry* **83**, 492–498 (2018).

13. Cardno, A. G. *et al.* Heritability estimates for psychotic disorders: the Maudsley twin

psychosis series. *Arch. Gen. Psychiatry* **56**, 162–168 (1999).

14. Lichtenstein, P. *et al.* Common genetic determinants of schizophrenia and bipolar

disorder in Swedish families: a population-based study. *Lancet* **373**, 234–239 (2009).

15. Legge, S. E. *et al.* Genetic architecture of schizophrenia: a review of major

advancements. *Psychol. Med.* **51**, 2168–2177 (2021).

16. Kendler, K. What psychiatric genetics has taught us about the nature of psychiatric

illness and what is left to learn. *Mol. Psychiatry* **18**, 1058–1066 (2013).

17. Alnæs, D. *et al.* Brain heterogeneity in schizophrenia and its association with polygenic

risk. *JAMA Psychiatry* **76**, 739–748 (2019).

18. Pergola, G., Penzel, N., Sportelli, L. & Bertolino, A. Lessons learned from parsing

genetic risk for schizophrenia into biological pathways. *Biol. Psychiatry* **94**, 121–130

(2023).

19. Owen, M. J., Legge, S. E., Rees, E., Walters, J. T. R. & O'Donovan, M. C. Genomic

findings in schizophrenia and their implications. *Mol. Psychiatry* **28**, 3638–3647 (2023).

20. Jablensky, A. Subtyping schizophrenia: implications for genetic research. *Mol.*

Psychiatry **11**, 815–836 (2006).

21. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in

schizophrenia. *Nature* **604**, 502–508 (2022).

22. O'Donovan, M. C. & Owen, M. J. The implications of the shared genetics of psychiatric

disorders. *Nat. Med.* **22**, 1214–1219 (2016).

23. Chen, J. *et al.* Polygenic risk scores for subtyping of schizophrenia. *Schizophr. Res.*

Treatment **2020**, 1638403 (2020).

24. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937

polygenic scores. *Nat. Commun.* **14**, 4702 (2023).

25. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated

population. *Nature* **613**, 508–518 (2023).

26. Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-scale

data. *GigaScience* **8**, (2019).

27. Zheng, Z. *et al.* Leveraging functional genomic annotations and genome coverage to

improve polygenic prediction of complex traits within and between ancestries. *Nat.*

Genet. **56**, 767–777 (2024).

28. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via

Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).

29. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics*

36, 5424–5431 (2021).

30. Budde, M. *et al.* A longitudinal approach to biological psychiatric research: The

PsyCourse study. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **180**, 89–102 (2019).

31. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and

traits. *Nat. Genet.* **47**, 1236–1241 (2015).

32. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from

polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

33. Wootton, O. *et al.* Genomic insights into the shared and distinct genetic architecture of

cognitive function and schizophrenia. *Sci. Rep.* **14**, 15356 (2024).

34. Andreassen, O. A. *et al.* Improved detection of common variants associated with

schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery

rate. *PLoS Genet.* **9**, e1003455 (2013).

35. Pruessner, M., Cullen, A. E., Aas, M. & Walker, E. F. The neural diathesis-stress model

of schizophrenia revisited: An update on recent findings considering illness stage and

neurobiological and methodological complexities. *Neurosci. Biobehav. Rev.* **73**, 191–

218 (2017).

36. Lederbogen, F., Haddad, L. & Meyer-Lindenberg, A. Urban social stress--risk factor for

mental disorders. The case of schizophrenia. *Environ. Pollut.* **183**, 2–6 (2013).

37. Lederbogen, F. *et al.* City living and urban upbringing affect neural social stress

processing in humans. *Nature* **474**, 498–501 (2011).

38. Antonucci, L. A. *et al.* Personality changes during adolescence predict young adult

psychosis proneness and mediate gene-environment interplays of schizophrenia risk.

Psychol. Med. **54**, 1–11 (2024).

39. Farmer, A. *et al.* Neuroticism, extraversion, life events and depression: The Cardiff

Depression Study. *Br. J. Psychiatry* **181**, 118–122 (2002).

40. Kendler, K. S., Kuhn, J. & Prescott, C. A. The interrelationship of neuroticism, sex, and

stressful life events in the prediction of episodes of major depression. *Am. J. Psychiatry*

161, 631–636 (2004).

41. Nagel, M. *et al.* Meta-analysis of genome-wide association studies for neuroticism in

449,484 individuals identifies novel genetic loci and pathways. *Nat. Genet.* **50**, 920–927

(2018).

42. Luciano, M. *et al.* Association analysis in over 329,000 individuals identifies 116

independent variants influencing neuroticism. *Nat. Genet.* **50**, 6–11 (2018).

43. Kappel, D. B. *et al.* Genomic stratification of clozapine prescription patterns using

schizophrenia polygenic scores. *Biol. Psychiatry* **93**, 149–156 (2023).

44. Uellendahl-Werth, F. *et al.* Cross-tissue transcriptome-wide association studies identify

susceptibility genes shared between schizophrenia and inflammatory bowel disease.

Commun. Biol. **5**, 80 (2022).

45. Gong, W. *et al.* Role of the gut-brain axis in the shared genetic etiology between

gastrointestinal tract diseases and psychiatric disorders: A genome-wide pleiotropic

analysis. *JAMA Psychiatry* **80**, 360–370 (2023).

46. Tylee, D. S. *et al.* An atlas of genetic correlations and genetically informed associations

linking psychiatric and immune-related phenotypes. *JAMA Psychiatry* **79**, 667–676

(2022).

47. Peterson, R. E. *et al.* Genome-wide association studies in ancestrally diverse

populations: Opportunities, methods, pitfalls, and recommendations. *Cell* **179**, 589–603

(2019).

48. Fatumo, S., Chikowore, T., Choudhury, A. & Ayub, M. A roadmap to increase diversity

in genomic studies. *Nat. Med.* (2022).

49. Sollis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and deposition

resource. *Nucleic Acids Res.* **51**, D977–D985 (2023).

50. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide

association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.*

47, D1005–D1012 (2019).

51. Malone, J. *et al.* Modeling sample variables with an Experimental Factor Ontology.

Bioinformatics **26**, 1112–1118 (2010).

52. Marees, A. T. *et al.* A tutorial on conducting genome-wide association studies: Quality

control and statistical analysis. *Int. J. Methods Psychiatr. Res.* **27**, e1608 (2018).

53. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk

score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).

54. Magno, R. & Maia, A.-T. gwasrapidd: an R package to query, download and wrangle

GWAS catalog data. *Bioinformatics* **36**, 649–650 (2020).

55. HannahVMeyer. *Meyer-Lab-cshl/plinkQC: plinkQC 0.3.2*. (Zenodo, 2020).

doi:10.5281/ZENODO.3934294.

56. Lam, M. *et al.* RICOPILI: Rapid imputation for COnsortias PIpeLIne. *Bioinformatics* **36**,

930–933 (2020).

57. Gnanadesikan, R. & Kettenring, J. R. Robust estimates, residuals, and outlier detection

with multiresponse data. *Biometrics* **28**, 81 (1972).

58. Leisch, F. Visualizing cluster results using package flexclust and friends. 116 (2009).

59. Breiman, L. Random Forests. *Mach. Learn.* **45**, 5–32 (2001).

60. Wright, M. N. & Ziegler, A. ranger: A Fast Implementation of Random Forests for High

Dimensional Data in C++ and R. *arXiv [stat.ML]* (2015).

61. Hubert, L. & Arabie, P. Comparing partitions. *J. Classif.* **2**, 193–218 (1985).

62. Rammstedt, B. & John, O. P. Measuring personality in one minute or less: A 10-item

short version of the Big Five Inventory in English and German. *J. Res. Pers.* **41**, 203–

212 (2007).

63. The R Project for Statistical Computing. http://www.R-project.org/.

64. The R Project for Statistical Computing. http://www.R-project.org/.

65. The 1000 Genomes Project Consortium *et al.* A global reference for human genetic

variation. *Nature* **526**, 68–74 (2015).

66. Smeland, O. B. *et al.* Discovery of shared genomic loci using the conditional false

discovery rate approach. *Hum. Genet.* **139**, 85–94 (2020).

67. Ho, D. E., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric Preprocessing for

Parametric Causal Inference. *J. Stat. Softw.* **42**, (2011).

68. Viechtbauer, W. Conducting Meta-Analyses inRwith themetaforPackage. *J. Stat. Softw.*

36, (2010).

Supplementary texts

Filtering criteria

The following filtering was used to include summary statistics in the analyses:

● European ancestry samples

● Total sample size > 10,000

● Summary statistics containing at least 250,000 SNPs

● The publication date is newer than January 1, 2018.

● Harmonized version.

● Number of cases > 5,000

Pre-imputation and imputation

FinnGen

FinnGen is a public-private partnership project between Finnish research institutes and
biobanks and private pharmaceutical companies. It leverages comprehensive Finnish digital
health care registers combined with genotypic data from 500k individuals. The diagnoses in
the registers are based on ICD-10, ICD-9 and ICD-8 criterion.
Samples were genotyped using Affymetrix (ThermoFisher Scientific) and Illumina arrays.
Imputation was performed using a reference panel specific to the Finnish population (SISu
v.4) based on 8,554 whole-genome-sequenced individuals resulting in 21 million imputed
variants for each participant. Sample QC involved the removal of participants whose genetic
sex did not match the ones provided in the registers, with a variant missingess of >2%,
heterozygosity of more than 4 SD from the mean in common variant (MAF > 0.05) or excess
relatedness to other samples (more than 500 relatives with PI_HAT > 0.1). Genetic variants
were pruned out if their allele frequencies significantly differed from the reference panel (p <
5e-8) adjusted for the first 10 principal components, it they had HWE p < 1e-10 or 15% of
the batches had a missinges > 0.04. Additionally, variants were removed within a batch if
HWE p-value was below 1e-6 or missingess was below 0.02. Each genotyping batch
consisted of ~5000 participants.

PsyCourse Study SCZ - Healthy control

The pre-imputation genotype data provided by the PsyCourse study included 428,904
genome-wide SNPs (GSA chip) from 1,600 individuals diagnosed with bipolar disorder, SCZ,
schizoaffective disorder, schizophreniform disorder and HC. From this dataset, 26 related
individuals were excluded, and SCZ patients (ICD-10 Schizophrenia and Schizophrenia
according to DSM-IV-TR) and HC born in European countries (PsyCourse codebook
variable : v1_cntr_brth) were selected, resulting in a final dataset of 755 individuals.

In the first QC-cycle of the imputation, Ricopili's pre-imputation module with default
parameters was executed. Thus, 500 SNPs and one individual failing to meet the criteria
were excluded from the dataset. In the next step, Ricopili's PCA module using default
parameters was executed to identify the outlier subjects. 31 outlier subjects were identified
and excluded that exceeded ±0.1 of the first two PCs. In the second QC-cycle, Ricopili's pre-
imputation module with default parameters was executed again and 84 SNPs failing to meet
the criteria were excluded from the dataset. The final pre-imputation dataset included 723
subjects and 428,320 SNPs.

As the final data met quality control criteria (lambda1000 = 1.014 and no genome-wide
significant SNPs were found), imputation was performed using the 1000 Genomes European
population as reference. Once the imputation was completed, SNPs with info scores above
0.8 (n = 4,883,969) were selected for post-imputation QC using our in-house genotype data
pre-processing module.

After completing the pre-processing module, the imputed and quality-controlled dataset
consisted of 3,470,953 SNPs and 725 individuals. That is, 1 individual (PSYCOURSE_0708)
and 1,413,016 SNPs, which did not meet the criteria specified in the genotype pre-
processing module, were removed from the post-imputation dataset. The final data included
721 individuals.

Bari Cohort

Subjects with European ancestry, comprising both healthy controls and individuals
diagnosed with SCZ or schizoaffective disorder, were recruited from the Apulia region in
Italy. The recruitment process followed the ethical standards outlined in the World Medical
Association's Declaration of Helsinki and was approved by the local ethics committee
("Comitato Etico Indipendente Locale - Azienda Ospedaliero-Universitaria Consorziale
Policlinico di Bari"). Healthy controls were screened using the Non-Patient Structured
Clinical Interview for DSM-IV to ensure they were unaffected by any psychiatric condition.
Diagnosis of SCZ was made using the Structured Clinical Interview for the DSM-IV, Axis 1
disorders by board-certified psychiatrists. Participants were excluded if they had a significant
history of drug or alcohol abuse, active substance use within the past year, a history of head
trauma with loss of consciousness, or any other serious medical condition. Genotype data
from Bari was collected over four years: 2015, 2016, 2017, and 2019. Genotyping for all
participants was conducted using the Illumina HumanOmni2.5-8 v1 BeadChip platform.
From the pre-imputation genotype data, subjects with SCZ and HC were selected from all
batches. SNP overlaps between batches were then compared, and those with the highest
overlap were combined, and imputed together. Accordingly, the batches from 2015 (557
individuals, 1,258,881 SNPs) and 2019 (154 individuals, 1,454,515 SNPs) were combined
and imputed together. Similarly, the batches from 2016 (139 individuals, 1,424,791 SNPs)
and 2017 (501 individuals, 1,431,583 SNPs) were merged and imputed together.

Dataset 1 (2015 together with 2019)

Pre-imputation data consisted of 1,197,491 overlapping SNPs between two batches and 711
individuals from Italy diagnosed with SCZ and HC.

1074

In the first QC-cycle, Ricopili's pre-imputation module with default parameters (except minor

allele frequency (MAF) > 0.02, because the lambda1000 value was high due to the genetic

inflation of SNPs with MAF values lower than this.) was executed. Thus, 59,089 SNPs failing

to meet the criteria were excluded from the dataset. In the next step, Ricopili's PCA module

using default parameters was executed to identify the related and outlier individuals. In total,

34 subjects were excluded from the data which were identified as related (pi-hat > 0.2). The

final pre-imputation dataset included 677 subjects and 1,138,402 SNPs.

As the final data met quality control criteria (lambda1000 = 1.022 and one genome-wide

significant SNPs was removed), imputation was performed using the 1000 Genomes

European population as reference. Once the imputation was completed, SNPs with info

scores above 0.8 (n = 7,892,583) were selected for merging with the Dataset 2.

Dataset 2 (2016 together with 2017)

Pre-imputation data consisted of 1,357,782 overlapping SNPs between two batches and 640

individuals from Italy diagnosed with SCZ and HC.

1089

In the first QC-cycle, Ricopili's pre-imputation module with default parameters (except MAF >
0.02, because the lambda1000 value was high due to the genetic inflation of SNPs with MAF
values lower than this.) was executed. Thus, 57,412 SNPs failing to meet the criteria were
excluded from the dataset. In the next step, Ricopili's PCA module using default parameters
was executed to identify the related and outlier individuals. In total, 21 subjects were
excluded from the data which were identified as related (pi-hat > 0.2). The final pre-
imputation dataset included 619 subjects and 1,300,370 SNPs.

As the final data met quality control criteria (lambda1000 = 0.979 and one genome-wide

significant SNPs was removed), imputation was performed using the 1000 Genomes

European population as reference. Once the imputation was completed, SNPs with info

scores above 0.8 (n = 8,147,504) were selected for merging with the Dataset 1.

Merging Dataset 1 and Dataset 2

Merging Dataset 1 and Dataset 2 resulted in a final dataset with 7,458,687 overlapping

SNPs and 1,296 subjects. Post-imputation QC was performed using our in-house genotype

data pre-processing module.

After completing the pre-processing module, the imputed and quality-controlled dataset

consisted of 5,432,607 SNPs and 1273 individuals. That is, 23 individuals and 2,026,080

SNPs, which did not meet the criteria specified in the genotype pre-processing module, were

removed from the post-imputation dataset. Four subjects whose deviations exceeded four

times the standard deviation based on PCs 1 and 2 were excluded, resulting in a final

sample of 1,269 subjects for analysis.

Intersecting SNPs across datasets

To minimize bias due to the differences in cohorts, only the SNPs that overlap across three

datasets were included in the PGS prediction. That is, 2,925,749 SNPs were included from

each dataset.

PGS Calculation Parameters

P-value thresholds : 5×10^{-8}, 1×10^{-7}, 1×10^{-6}, 1×10^{-5}, 1×10^{-4}, 0.001, 0.01, 0.05, 0.1, 0.5, 1 (--

bar-levels)

Clumping : 500 (--clump-kb), 1 (--clump-p), 0.2 (clump-r2)

MAF filtering : 0.01 (--base-maf), MAFs of the SNPs in a GWAS summary statistics were

calculated from 1000 Genome European population reference dataset.

LD reference file : 1000 Genome European population reference dataset.

Supplementary Figures

1123

1124 **Supplementary Figure 1. The dendrogram of the hierarchical clustering of the absolute**
1125 **genetic correlation matrix**. The group second on the right contains SCZ itself, a gene-
1126 environment interaction GWAS and two measures related to alcohol use. For clearer
1127 interpretation of selected downstream analyses characterizing the contribution of the different
1128 PGS-groups, we investigated SCZ as a single PGS.

1129

Supplementary Figure 2. Genetic correlations between the top 45 source GWAS. Note that Supplementary Figure 21 is not based on the genetic correlation values plotted here but on the absolute values.

1133
Supplementary Figure 3. Feature size 1: Differences in comorbidity rates of mental disorders and disorder categories between the biotypes. Red color indicates statistical significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1137

Supplementary Figure 4. Feature size 2: Differences in comorbidity rates of mental disorders and disorder categories between the biotypes. Red color indicates statistical significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1141

Supplementary Figure 5. Feature size 3: Differences in comorbidity rates of mental disorders and disorder categories between the biotypes. Red color indicates statistical significance at FDR of 0.05. The error bars show 95 % confidence intervals.

Supplementary Figure 6 . Feature size 4: Differences in comorbidity rates of mental disorders and disorder categories between the biotypes. Red color indicates statistical significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1149

1150 **Supplementary Figure 7. Feature size 5: Differences in comorbidity rates of mental**

1151 **disorders and disorder categories between the biotypes.** Red color indicates statistical

1152 significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1153

Supplementary Figure 8. Feature size 6: Differences in comorbidity rates of mental disorders and disorder categories between the biotypes. Red color indicates statistical significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1157
Supplementary Figure 9. Feature size 12: Differences in comorbidity rates of mental disorders and disorder categories between the biotypes. Red color indicates statistical significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1161
Supplementary Figure 10. Feature size 24: Differences in comorbidity rates of mental disorders and disorder categories between the biotypes. Red color indicates statistical significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1165

Supplementary Figure 11. Feature size 33: Differences in comorbidity rates of mental

disorders and disorder categories between the biotypes. Red color indicates statistical

significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1169
1170 **Supplementary Figure 12. Feature size 45: Differences in comorbidity rates of mental**

1171 **disorders and disorder categories between the biotypes.** Red color indicates statistical

1172 significance at FDR of 0.05. The error bars show 95 % confidence intervals.

1173
Supplementary Figure 13. Difference in Clozapine and antidepressants prescription rates between the biotypes across feature sizes.

1176

Supplementary Figure 14. Differential diagnostic associations of SCZ biotypes across feature sizes. Note that feature size 12 is depicted in Figure 5.

1179
1180 **Supplementary Figure 15. Clozapine and antidepressant use association in Val$_{PsyCourse}$**
1181 **across all feature sizes.** The error bars show 95 % confidence intervals.

1182

Supplementary Figure 16. PANSS cluster associations in Val$_{PsyCourse}$ across all feature sizes. The error bars show 95 % confidence intervals.

1185
1186   **Supplementary Figure 17. PANSS cluster associations in Val$_{Bari}$ across all feature sizes.**

1187   The error bars show 95 % confidence intervals.

1188

1189 **Supplementary Figure 18. Cluster associations of selected phenotypes in Val$_{PsyCourse}$**

1190 **across all feature sizes.** The error bars show 95 % confidence intervals.

1191

Supplementary Figure 19. **Automated GWAS search module workflow.**

1193

Supplementary Figure 20. **Summary statistics QC module workflow.**

Genotype Data Pre-Processing Module

QC Steps

- Soft filtering
  - Filters out all variants with missing call rates exceeding the provided value (0.2)
  - Filters out all samples with missing call rates exceeding the provided value (0.2)
- Strict filtering
  - Filter out variants missing call rates > 0.02
  - Filter out samples missing call rates > 0.02
  - Filter out variants Hardy-Weinberg equilibrium exact test p-value $< 10^{-6}$
  - Exclude Chr.8 inversion (8:7-13Mb) and
  - Filter out variants with heterozygosity rates exceeding the three times of the standard deviation
- To assess relatedness between samples, we pruned SNPs to ensure minimal linkage disequilibrium between SNPs (R² < 0.2).
  - Exclude Chr.8 inversion (8:7-13Mb) and major histocompatibility complex (MHC) region (6:28-34Mb)
  - LD - R^2 < 2, 200 SNPs window: plink --indep-pairwise 200 100 0.2
  - Filter out samples which are related (PI_HAT value < 0.2)
- exclude MHC (6:28-34Mb) from the final version

Calculate Population Stratifacation Effect

- Remove multi-nucleotide variants
- Remove ambiguous SNPs
- Convert variant id into CHR:POS format
- Remove duplicate SNPs
- Calculate principal components before population stratification
- Exclude Chr.8 inversion (8:7-13Mb) and MHC (6:28-34Mb)
- Include SNPs minor alllele frequency > 0.05
- Filter out variants Hardy-Weinberg equilibrium exact test p-value $< 10^{-3}$
- Filter out variants missing call rates > 0.02
- Pruning to ensure minimal linkage disequilibrium between SNPs (R² < 0.2)
  - LD - R^2 < 2, 200 SNPs window: plink --indep-pairwise 200 100 0.2
  - Repeat LD pruning with resulting LD pruned dataset
  - If number of SNPs is still over 100K SNPs, prune randomly

Output

- QCed genotype data
- PCs and their plots, before and after population stratification calculation
- SNP missingness rate distribution plot
- Heterozygosity distribution plot
- Sample missingness rate distribution plot
- Minor allele frequency distribution plot of the SNPs

1195

1196 **Supplementary Figure 21. Genotype QC module workflow.**

1197
1198 **Supplementary Figure 22. Feature selection by ranking GWASs according to best PGS.**